The role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis

George H. Thompson, Ivan Florentino, Connie Poe-Kochert

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Study Design. Four separate studies on the role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. Objectives. To assess the efficacy and possible mechanisms of action for Amicar. Summary of Background Data. Preliminary prospective, randomized double-blind and analysis of same-day anterior spinal fusion (ASF), fibrinogen, and posterior spinal fusion (PSF) studies have demonstrated Amicar to be effective in idiopathic scoliosis surgery. Increased fibrinogen secretion is a possible explanation. Methods. Amicar is administered at 100 mg/kg over 15 minutes not to exceed 5 g at anesthesia induction. Maintenance is 10 mg/kg per hour until wound closure. Results. Preliminary study: Amicar (N = 28) was effective compared with a control group (N = 31). Perioperative blood loss and transfusion following PSF were 1,604 ± 517 mL and 1.1 ± 1.0 U in the Amicar group compared with 2,312 ± 994 mL and 2.1 ± 1.1 U in the control group (P < 0.003). Prospective, randomized double-blind study confirmed this efficacy, although primarily in postoperative suction drainage: 1,391 ± 212 mL and 1.1 ± 1.0 U compared with 1,716 ± 513 mL and 2.1 ± 1.3 U (P < 0.002). A fibrinogen study (N = 21) demonstrated steady and excessive increase following PSF: before surgery it was 266 ± 63 mg/dL and on the fifth postoperative day 699 ± 94 mg/dL. In same-day anterior and posterior spinal surgery, Amicar was again effective, but primarily in decreasing chest tube drainage and during PSF. Group 1 (N = 15, no Amicar) 3,807 ± 105 mL and 3.1 ± 1.5 U; Group 2 (N = 27, Amicar for PSF only) 2,080 ± 659 mL and 1.9 ± 0.9 U; and Group 3 (N = 16, both ASF and PSF) 2,183 ± 851 mL and 1.0 ± 0.8 U. Conclusions. Amicar appears highly effective in decreasing perioperative blood loss. This results in less autologous blood donation, blood transfusion, costs, and complications. Its mechanism of action is uncertain but may be; related to increased fibrinogen secretion.

Original languageEnglish (US)
JournalSpine
Volume30
Issue number17 SUPPL.
StatePublished - Sep 1 2005

Fingerprint

Aminocaproic Acid
Scoliosis
Spinal Fusion
Fibrinogen
Blood Transfusion
Chest Tubes
Control Groups
Suction
Blood Donors
Double-Blind Method
Drainage
Anesthesia
Maintenance

Keywords

  • Adolescent idiopathic scoliosis
  • Amicar (epsilon aminocaproic acid)
  • Perioperative blood loss fibrinogen
  • Posterior spinal fusion
  • Same-day anterior and posterior spinal fusion
  • Segmental spinal instrumentation

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Clinical Neurology

Cite this

The role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. / Thompson, George H.; Florentino, Ivan; Poe-Kochert, Connie.

In: Spine, Vol. 30, No. 17 SUPPL., 01.09.2005.

Research output: Contribution to journalArticle

Thompson, George H. ; Florentino, Ivan ; Poe-Kochert, Connie. / The role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. In: Spine. 2005 ; Vol. 30, No. 17 SUPPL.
@article{776a37a29f594bd8b6f8b17684ed1cab,
title = "The role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis",
abstract = "Study Design. Four separate studies on the role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. Objectives. To assess the efficacy and possible mechanisms of action for Amicar. Summary of Background Data. Preliminary prospective, randomized double-blind and analysis of same-day anterior spinal fusion (ASF), fibrinogen, and posterior spinal fusion (PSF) studies have demonstrated Amicar to be effective in idiopathic scoliosis surgery. Increased fibrinogen secretion is a possible explanation. Methods. Amicar is administered at 100 mg/kg over 15 minutes not to exceed 5 g at anesthesia induction. Maintenance is 10 mg/kg per hour until wound closure. Results. Preliminary study: Amicar (N = 28) was effective compared with a control group (N = 31). Perioperative blood loss and transfusion following PSF were 1,604 ± 517 mL and 1.1 ± 1.0 U in the Amicar group compared with 2,312 ± 994 mL and 2.1 ± 1.1 U in the control group (P < 0.003). Prospective, randomized double-blind study confirmed this efficacy, although primarily in postoperative suction drainage: 1,391 ± 212 mL and 1.1 ± 1.0 U compared with 1,716 ± 513 mL and 2.1 ± 1.3 U (P < 0.002). A fibrinogen study (N = 21) demonstrated steady and excessive increase following PSF: before surgery it was 266 ± 63 mg/dL and on the fifth postoperative day 699 ± 94 mg/dL. In same-day anterior and posterior spinal surgery, Amicar was again effective, but primarily in decreasing chest tube drainage and during PSF. Group 1 (N = 15, no Amicar) 3,807 ± 105 mL and 3.1 ± 1.5 U; Group 2 (N = 27, Amicar for PSF only) 2,080 ± 659 mL and 1.9 ± 0.9 U; and Group 3 (N = 16, both ASF and PSF) 2,183 ± 851 mL and 1.0 ± 0.8 U. Conclusions. Amicar appears highly effective in decreasing perioperative blood loss. This results in less autologous blood donation, blood transfusion, costs, and complications. Its mechanism of action is uncertain but may be; related to increased fibrinogen secretion.",
keywords = "Adolescent idiopathic scoliosis, Amicar (epsilon aminocaproic acid), Perioperative blood loss fibrinogen, Posterior spinal fusion, Same-day anterior and posterior spinal fusion, Segmental spinal instrumentation",
author = "Thompson, {George H.} and Ivan Florentino and Connie Poe-Kochert",
year = "2005",
month = "9",
day = "1",
language = "English (US)",
volume = "30",
journal = "Spine",
issn = "0362-2436",
publisher = "Lippincott Williams and Wilkins",
number = "17 SUPPL.",

}

TY - JOUR

T1 - The role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis

AU - Thompson, George H.

AU - Florentino, Ivan

AU - Poe-Kochert, Connie

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Study Design. Four separate studies on the role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. Objectives. To assess the efficacy and possible mechanisms of action for Amicar. Summary of Background Data. Preliminary prospective, randomized double-blind and analysis of same-day anterior spinal fusion (ASF), fibrinogen, and posterior spinal fusion (PSF) studies have demonstrated Amicar to be effective in idiopathic scoliosis surgery. Increased fibrinogen secretion is a possible explanation. Methods. Amicar is administered at 100 mg/kg over 15 minutes not to exceed 5 g at anesthesia induction. Maintenance is 10 mg/kg per hour until wound closure. Results. Preliminary study: Amicar (N = 28) was effective compared with a control group (N = 31). Perioperative blood loss and transfusion following PSF were 1,604 ± 517 mL and 1.1 ± 1.0 U in the Amicar group compared with 2,312 ± 994 mL and 2.1 ± 1.1 U in the control group (P < 0.003). Prospective, randomized double-blind study confirmed this efficacy, although primarily in postoperative suction drainage: 1,391 ± 212 mL and 1.1 ± 1.0 U compared with 1,716 ± 513 mL and 2.1 ± 1.3 U (P < 0.002). A fibrinogen study (N = 21) demonstrated steady and excessive increase following PSF: before surgery it was 266 ± 63 mg/dL and on the fifth postoperative day 699 ± 94 mg/dL. In same-day anterior and posterior spinal surgery, Amicar was again effective, but primarily in decreasing chest tube drainage and during PSF. Group 1 (N = 15, no Amicar) 3,807 ± 105 mL and 3.1 ± 1.5 U; Group 2 (N = 27, Amicar for PSF only) 2,080 ± 659 mL and 1.9 ± 0.9 U; and Group 3 (N = 16, both ASF and PSF) 2,183 ± 851 mL and 1.0 ± 0.8 U. Conclusions. Amicar appears highly effective in decreasing perioperative blood loss. This results in less autologous blood donation, blood transfusion, costs, and complications. Its mechanism of action is uncertain but may be; related to increased fibrinogen secretion.

AB - Study Design. Four separate studies on the role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. Objectives. To assess the efficacy and possible mechanisms of action for Amicar. Summary of Background Data. Preliminary prospective, randomized double-blind and analysis of same-day anterior spinal fusion (ASF), fibrinogen, and posterior spinal fusion (PSF) studies have demonstrated Amicar to be effective in idiopathic scoliosis surgery. Increased fibrinogen secretion is a possible explanation. Methods. Amicar is administered at 100 mg/kg over 15 minutes not to exceed 5 g at anesthesia induction. Maintenance is 10 mg/kg per hour until wound closure. Results. Preliminary study: Amicar (N = 28) was effective compared with a control group (N = 31). Perioperative blood loss and transfusion following PSF were 1,604 ± 517 mL and 1.1 ± 1.0 U in the Amicar group compared with 2,312 ± 994 mL and 2.1 ± 1.1 U in the control group (P < 0.003). Prospective, randomized double-blind study confirmed this efficacy, although primarily in postoperative suction drainage: 1,391 ± 212 mL and 1.1 ± 1.0 U compared with 1,716 ± 513 mL and 2.1 ± 1.3 U (P < 0.002). A fibrinogen study (N = 21) demonstrated steady and excessive increase following PSF: before surgery it was 266 ± 63 mg/dL and on the fifth postoperative day 699 ± 94 mg/dL. In same-day anterior and posterior spinal surgery, Amicar was again effective, but primarily in decreasing chest tube drainage and during PSF. Group 1 (N = 15, no Amicar) 3,807 ± 105 mL and 3.1 ± 1.5 U; Group 2 (N = 27, Amicar for PSF only) 2,080 ± 659 mL and 1.9 ± 0.9 U; and Group 3 (N = 16, both ASF and PSF) 2,183 ± 851 mL and 1.0 ± 0.8 U. Conclusions. Amicar appears highly effective in decreasing perioperative blood loss. This results in less autologous blood donation, blood transfusion, costs, and complications. Its mechanism of action is uncertain but may be; related to increased fibrinogen secretion.

KW - Adolescent idiopathic scoliosis

KW - Amicar (epsilon aminocaproic acid)

KW - Perioperative blood loss fibrinogen

KW - Posterior spinal fusion

KW - Same-day anterior and posterior spinal fusion

KW - Segmental spinal instrumentation

UR - http://www.scopus.com/inward/record.url?scp=24744458362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24744458362&partnerID=8YFLogxK

M3 - Article

C2 - 16138073

AN - SCOPUS:24744458362

VL - 30

JO - Spine

JF - Spine

SN - 0362-2436

IS - 17 SUPPL.

ER -